Promising Findings on Kidney Function Preservation in IgA Nephropathy Patients at National Kidney Foundation Spring Clinical Meetings

Spring Clinical Meetings 2024

Long Beach, CA - May 15, 2024 - A new study to shed light on the long-term nephroprotective potential of sparsentan compared to maximally titrated irbesartan (MT-IRB) in patients with IgA nephropathy (IgAN) is set to be presented as a late-breaking presentation at the National Kidney Foundation 2024 Spring Clinical Meetings.

"Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study With UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd" delves into the comparison of 2-year estimated glomerular filtration rate (eGFR) total slopes between the sparsentan and MT-IRB arms of the PROTECT clinical trial and standard of care (SoC) in real-world and clinical trial settings. The work was conducted by a collaborative team of researchers from Travere Therapeutics, Analysis Group, JAMCO Pharma Consulting, Ohio State University, and the University of Leicester.

The PROTECT trial was specifically designed to assess the long-term nephroprotective effects of sparsentan compared to MT-IRB in IgAN patients. By comparing outcomes with real-world data from the UK National Registry of Rare Kidney Diseases (RaDaR) patients with IgAN and a comparable clinical trial population (NefIgArd), researchers aimed to evaluate the efficacy of sparsentan and MT-IRB in preserving kidney function in a broader context.

Using unanchored matching-adjusted indirect comparisons, researchers matched baseline patient characteristics between the PROTECT trial arms and the comparator populations. The results revealed that patients treated with MT-IRB or sparsentan in the PROTECT trial exhibited a significantly slower decline in kidney function compared to standard of care in both real-world and a clinical trial setting.

These findings highlight the potential of MT-IRB and sparsentan in slowing the progression of kidney function decline in IgAN patients, offering promising insights for improved treatment strategies and patient care.

The findings underscore the importance of considering 2-year eGFR slope differences between clinical trials in IgAN within the broader context of current clinical practice. It also opens avenues for further research and advancements in the management of IgA nephropathy.

About NKF Spring Clinical Meetings
For the past 32 years, nephrology healthcare professionals from across the country have come to NKF’s Spring Clinical Meetings to learn about the newest developments related to all aspects of nephrology practice; network with colleagues; and present their research findings. The NKF Spring Clinical Meetings is designed for meaningful change in the multidisciplinary healthcare teams’ skills, performance, and patient health outcomes. It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team.

About Kidney Disease
In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don’t know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabeteshigh blood pressureheart diseaseobesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people.

About NKF Professional Memberships
Healthcare professionals can join NKF to receive access to tools and resources for both patients and professionals, discounts on professional education, and access to a network of thousands of individuals who treat patients with kidney disease. 

About the National Kidney Foundation
The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation.



Paul McGee 716.523.6874   
Karla Thomas 773.575.9477